Alendronate induced subacute cutaneous lupus erythematosus successfully treated with intravenous immunoglobulin. Issue 6 (5th November 2020)

• Record Type: Journal Article
• Authors: Uzuncakmak, Tugba Kevser; Bayazit, Samet; Askin, Ozge; Engin, Burhan; Ugurlu, Serdal; Sar, Mehmet; Serdaroglu, Server
• Is Part Of: Dermatologic therapy. Volume 33:Issue 6(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-11-05
• Subjects: dapsone -- dermatology -- dermatopathology -- discoid lupus -- intravenous immunoglobulin -- mycophenolate mofetil -- subacute cutaneous lupus erythematosus; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.14477
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: The subacute cutaneous lupus erythematosus (SCLE) is a distinct subtype of lupus erythematosus (LE) representing specific clinical and serological features. Almost 20%‐30% of the cases with SCLE are predicted to associated with medications. Thiazide diuretics, terbinafine, antiepileptic, and proton pump inhibitors are the best‐known drugs to induce drug‐related SCLE. Herein we want to present a 65‐year‐old female with alendronate induced SCLE, resistant to classical therapies, and respond well to intravenous immunoglobulin (IVIG), suggesting that IVIG could be an alternative treatment in patients resistant to classical treatment protocols.